^
3d
Cytofluorometric analysis of the maturation and activation of bone marrow-derived dendritic cells to assess immunogenic cell death. (PubMed, Methods Cell Biol)
In this chapter, we provide straightforward methodologies to isolate DCs from murine bone marrow (bone marrow-derived DCs, BMDCs), induce immunogenic apoptosis in murine MCA205 fibrosarcoma cells using ICD inducer mitoxantrone (MTX), co-cultivate BMDCs with the MTX-treated cancer cells, and to assess the activation and maturation status of BMDCs by flow cytometric-assisted quantification of co-stimulatory molecules (MHC II, CD86, CD80) expressed on the plasma membrane of BMDCs. With minor adjustments, the same protocol can be implemented to other cancer cell lines or to analyze the phenotypic status of non-professional APCs.
Journal
|
CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
|
mitoxantrone
12d
Gold(I) somplexes of the type [AuL{κC-2-C6H4P(S)Ph2}] [L = PTA, PPh3, PPh2(C6H4-3-SO3Na) and PPh2(2-py)]: Synthesis, characterisation, crystal structures, and In Vitro and In Vivo anticancer properties. (PubMed, Eur J Med Chem)
In vivo studies using mouse xenograft models showed that complex 1 displayed superior inhibition of tumour growth (82 %) compared to the clinical drug cisplatin (29 %). Overall, these results highlight the potential of gold (I) compounds as novel antitumour agents.
Preclinical • Journal
|
FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
|
cisplatin
13d
Chapter 13: What is new in fibroblastic/myofibroblastic tumors in children. (PubMed, Virchows Arch)
Furthermore, new RTK-driven lesions, now included in the WHO's "NTRK-rearranged mesenchymal neoplasms", have been identified. This review provides an update on recent findings in RTK-driven myofibroblastic tumors and highlights novel entities still in need of classification.
Review • Journal
|
NTRK (Neurotrophic receptor tyrosine kinase)
14d
Primary intracranial dedifferentiated liposarcoma: An extremely rare site with unusual histopathological findings. (PubMed, Neuropathology)
Final diagnosis of DDLS was rendered. The patient had no systemic lesions elsewhere on positron emission tomography computed tomography scan.
Journal
|
MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • GFAP (Glial Fibrillary Acidic Protein) • OLIG2 (Oligodendrocyte Transcription Factor 2)
|
MDM2 amplification
19d
Ganglioglioma with MAP2K1 Mutation and CDKN2A/B Homozygous Deletion: A Case Report. (PubMed, Br J Hosp Med (Lond))
Subsequently, salvage chemotherapy with a combination of temozolomide and irinotecan was administered, resulting in effective control of the tumor. Conclusion To our knowledge, this is the first reported case of ganglioglioma with anaplastic features harboring MAP2K1 mutation and homozygous deletion of CDKN2A/B. These findings may shed light on the genetic features of ganglioglioma and offers insights into potential therapeutic approaches for this rare neoplasm.
Journal
|
BRAF (B-raf proto-oncogene) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
|
BRAF V600E • BRAF V600 • CDKN2A deletion • CDKN2A mutation
|
temozolomide • irinotecan
19d
Clinicopathological, Histopathological, and Immunohistochemical Analysis of Mandibular Fibrosarcoma in a DSH Cat: A Case Report. (PubMed, Vet Med Sci)
A five-day course of adjunctive treatment, including ceftriaxone (5.5 mg/kg via IV) and clindamycin (25 mg/kg via IV), was given due to a suspicion of infection. Pantoprazole, metoclopramide (administered at 1 mg/kg via IV and IM), and duphalyte 500 mL (10 mL/kg IV) were used concurrently to alleviate nausea and stimulate appetite...Immunohistochemical staining was positive for the vimentin marker, the S-100 protein, and desmin. This report describes a rare case of oral fibrosarcoma in a DSH cat in Iran.
Journal
|
VIM (Vimentin)
20d
ADVL1823: Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia (clinicaltrials.gov)
P2, N=70, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2024 --> Sep 2025
Trial completion date
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ETV6 (ETS Variant Transcription Factor 6)
|
NTRK1 fusion • NTRK3 fusion • NTRK2 fusion
|
Vitrakvi (larotrectinib)
24d
Are Ameloblastic Fibroma-related Lesions True Tumors?: Evidence Through CNA and BRAF Mutation Analysis. (PubMed, Am J Surg Pathol)
Profiling copy number alterations in AF and related lesions emerge as a valuable tool for enhancing their differential diagnosis and facilitating the anticipation of disease progression. Our findings underscore the efficacy of copy number alteration analysis in determining the nature of lesions within AF and related lesions.
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF mutation • BRAF V600 • BRAF wild-type
26d
Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy. (PubMed, Sci Transl Med)
Concomitant inhibition of both FAK (with VS-4718) and rapidly accelerated fibrosarcoma and MAPK kinase (RAF-MEK) (with avutometinib) induced tumor growth inhibition and increased survival across multiple PDAC mouse models. Combination of FAK and RAF-MEK inhibition alone improved antitumor immunity and priming of T cell responses in response to chemotherapy. These findings provided the rationale for an ongoing clinical trial evaluating the efficacy of avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in patients with PDAC and may suggest further paths for combined stromal and tumor-targeting therapies.
Journal • Stroma
|
KRAS (KRAS proto-oncogene GTPase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
KRAS mutation
|
gemcitabine • albumin-bound paclitaxel • avutometinib (VS-6766) • defactinib (VS-6063) • VS-4718
27d
eIF4F controls ERK MAPK signaling in melanomas with BRAF and NRAS mutations. (PubMed, Proc Natl Acad Sci U S A)
Furthermore, our quantitative analyses reveal a high spare signaling capacity in the ERK pathway, suggesting that eIF4F-dependent feedback keeps the majority of ERK molecules inactive under normal conditions. Overall, our findings highlight the crucial role of eIF4F in regulating ERK signaling flux and suggest that pharmacological eIF4F inhibitors can disrupt the negative feedback control of MAPK activity in melanomas with BRAF and NRAS activating mutations.
Journal
|
BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • DUSP6 (Dual specificity phosphatase 6) • EGR1 (Early Growth Response 1) • EIF4G1 (Eukaryotic translation initiation factor 4 gamma, 1)
|
BRAF mutation • NRAS mutation • RAS mutation • NRAS mutation + BRAF mutation
1m
Ursolic acid interaction with transcription factors BRAF, V600E, and V600K: a computational approach towards new potential melanoma treatments. (PubMed, J Mol Model)
Due to the relevance of the BRAFV600E mutation, inhibitors to this kinase have been developed, vemurafenib-OMe and dabrafenib. Ligand-protein interactions were evaluated using Schrödinger-Maestro program, LigPlot + , and PLIP (protein-ligand interaction profiler). Finally, all of the protein figures presented in this article were made in the PyMOL program.
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • BRAF V600K • BRAF wild-type • BRAF V600 wild-type • BRAF V600E + BRAF V600K
|
Zelboraf (vemurafenib) • Tafinlar (dabrafenib)
1m
S100 and CD34 positive spindle cell tumors of the uterine cervix with EGFR mutation: a hitherto unrecognized neoplasm phenotypically and epigenetically overlapping with "NTRK-rearranged spindle cell neoplasms" of the uterus. (PubMed, Virchows Arch)
The patient in case 2 had no other known tumors at the time of diagnosis, but no follow-up is available. We believe the reported cases represent a hitherto unrecognized variant of "NTRK-rearranged spindle cell neoplasms" of the uterine cervix with novel EGFR mutations.
Journal
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD34 (CD34 molecule) • SOX10 (SRY-Box 10) • NTRK (Neurotrophic receptor tyrosine kinase)
|
EGFR mutation • BRAF mutation • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • RET fusion • TNFRSF8 expression • EGFR exon 20 mutation • CD34 positive
1m
High-Throughput Hybridization Assay as First-Line Diagnostic Test for Sarcomas: Clinical Assessment in a Tertiary Referral Center. (PubMed, Arch Pathol Lab Med)
It is a cost-effective assay with rapid turnaround time, low sample consumption, streamlined analysis, and easy customization. Therefore, it is a promising alternative first-line diagnostic tool for routine sarcoma testing.
Journal
|
STAT6 (Signal transducer and activator of transcription 6) • CREB3L1 (CAMP Responsive Element Binding Protein 3 Like 1) • EGR1 (Early Growth Response 1) • NAB2 (NGFI-A Binding Protein 2)
2ms
PRAME expression in fibrosarcomatous dermatofibrosarcoma protuberans. (PubMed, Sci Rep)
Double staining of CD34 and PRAME revealed that PRAME-positive and CD34-positive areas did not overlap. This is the largest study to examine PRAME expression in FS-DFSP, and it confirmed the usefulness of PRAME in diagnosing this condition.
Journal • IO biomarker
|
CD34 (CD34 molecule) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
CD34 positive • PRAME expression
2ms
Dermatofibrosarcoma Protuberans: An Updated Review of the Literature. (PubMed, Cancers (Basel))
Another main point of this review is that cases of DFSP with fibrosarcomatous transformation are a challenge and require careful medical attention. Both anatomopathological evaluation of the presence of lymphovascular space invasion and sentinel lymph node biopsy at DFSP surgery merit further study.
Review • Journal
|
COL1A1 (Collagen Type I Alpha 1 Chain) • PDGFB (Platelet Derived Growth Factor Subunit B)
|
COL1A1-PDGFB fusion
2ms
Non-thermal atmospheric pressure plasma induces selective cancer cell apoptosis by modulating redox homeostasis. (PubMed, Cell Commun Signal)
Our study demonstrates that NTAPP induces selective cell death in fibrosarcoma cells through the downregulation of the NRF2-induced ROS scavenger system and inhibition of autophagy. These findings suggest NTAPP's potential as a cancer therapy that minimizes damage to normal cells while effectively targeting cancer cells.
Journal
|
NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
2ms
Sclerosing Epithelioid Fibrosarcoma Harboring the EWSR1-CREB3L1 Gene Fusion: The Importance of Molecular Classification in Pediatric Sarcomas. (PubMed, J Pediatr Hematol Oncol)
SEF is typically identified via genetic testing and recognition of the EWSR1-CREB3L1 gene fusion as well as MUC4 expression via immunohistochemistry. DNA methylation profiling, which has traditionally been used in brain tumors, can also efficiently identify this tumor, and we recommend expanding the use of this technology for difficult to classify pediatric sarcomas.
Journal
|
EWSR1 (EWS RNA Binding Protein 1) • MUC4 (Mucin 4, Cell Surface Associated) • CREB3L1 (CAMP Responsive Element Binding Protein 3 Like 1)
|
MUC4 expression
2ms
Journal
|
HCFC1 (Host Cell Factor C1)
2ms
The oncogenic fusion protein EML4-NTRK3 requires three salt bridges for stability and biological activity. (PubMed, Heliyon)
We also demonstrate that EML4-NTRK3 is localized in the cytoplasm and fails to associate with microtubules. These data suggest potential therapeutic strategies for Infantile Fibrosarcoma cases bearing EML4-NTRK3 fusion through inhibition of salt bridge interactions and disruption of multimerization.
Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • EML4 (EMAP Like 4) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK3 fusion • EML4-NTRK3 fusion • NTRK3 translocation
2ms
PHF1::TFE3-positive fibromyxoid sarcoma? Report of 2 cases and review of 13 cases of PHF1::TFE3-positive ossifying fibromyxoid tumor in the literature. (PubMed, Am J Clin Pathol)
Because PHF1 is located at 3' in all the PHF1 fusions in OFMTs except PHF1::TFE3, the different driver molecular alterations suggest that OFMTs with 3'-PHF1 fusions and OFMTs with PHF1::TFE3 are different tumors. Immunohistochemistry confirmed TFE3 expression in all PHF1::TFE3 OFMTs. Because PHF1::TFE3-positive OFMTs have increased mitotic figures and tumor cellularity, with a high rate of metastasis, using the name PHF1::TFE3 positive fibromyxoid sarcoma may be appropriate.
Review • Journal
|
TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • EP400 (E1A Binding Protein P400)
|
TFE3 fusion
2ms
Pediatric Fibromatosis Lacks the Internal Tandem Duplication of EGFR Seen in Congenital Mesoblastic Nephroma. (PubMed, Genes Chromosomes Cancer)
The soft tissue tumors with EGFR ITD are not a morphologic match for the low-grade histology of classical CMN. Whether they have a similar favorable biology or behave more like fibrosarcoma with an ETV6::NTRK3 fusion or an alternative fusion involving other kinases remains to be determined.
Journal
|
EGFR (Epidermal growth factor receptor) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
|
NTRK3 fusion • EGFR positive
2ms
MAFB in Macrophages Regulates Prostaglandin E2-Mediated Lipid Mediator Class Switch through ALOX15 in Ischemic Acute Kidney Injury. (PubMed, J Immunol)
Therefore, MAFB plays a key role in the PGE2-mediated LM class switch by regulating the expression of Alox15. Our study identified a previously unknown mechanism by which MAFB in macrophages alleviates ischemic AKI and provides new insights into regulating the LM class switch in acute inflammatory conditions.
Journal
|
MAFB (MAF BZIP Transcription Factor B) • ALOX15 (Arachidonate 15-Lipoxygenase)
|
MAFB expression
3ms
Garlic Extract Promotes Pancreatic Islet Neogenesis Through α-to-β-Cell Transdifferentiation and Normalizes Glucose Homeostasis in Diabetic Rats. (PubMed, Mol Nutr Food Res)
GE induces β-cell neogenesis in DRs and restores islet architecture. The newly formed mature β-like cells could have originated through the differentiation of endocrine progenitor cells as well as α- to β-cell transdifferentiation.
Preclinical • Journal
|
MAFB (MAF BZIP Transcription Factor B) • PDX1 (Pancreatic And Duodenal Homeobox 1) • NEUROD1 (Neuronal Differentiation 1) • NEUROG3 (Neurogenin 3) • GCG (Glucagon)
3ms
Stimulator of Interferon Genes-Activated Biomimetic Dendritic Cell Nanovaccine as a Chemotherapeutic Booster to Enhance Systemic Fibrosarcoma Treatment. (PubMed, ACS Nano)
Anthracycline drugs, such as doxorubicin (DOX), represent the frontline chemotherapy for fibrosarcoma, but often exhibit suboptimal efficacy...Hence, these findings demonstrate the potential of DC nanovaccine GP@CRTM as a booster for chemotherapy. Synergistically combining low-dose DOX with the DC nanovaccine emerges as a powerful chemo-immunotherapy strategy, optimizing systemic fibrosarcoma therapy.
Journal
|
STING (stimulator of interferon response cGAMP interactor 1) • CALR (Calreticulin)
|
doxorubicin hydrochloride
3ms
Identification of Isoliensinine as a Ferroptosis Suppressor with Iron-Chelating Activity. (PubMed, J Nat Prod)
Here, we performed a natural product library screening in HT1080 fibrosarcoma cells and identified licochalcone A (LA), isoeugenyl acetate (ISA), and isoliensinine (ISL) as suppressors of either RSL3- or IKE-induced ferroptosis...Furthermore, its iron chelator activity also protected mice from organ injury in an acute iron overload model. In conclusion, this study provided valuable insights for developing effective anti-ferroptosis agents from natural products, which represent a potential therapeutic strategy for treating ferroptosis-associated organ damage.
Journal
|
GPX4 (Glutathione Peroxidase 4)
|
RSL3
3ms
Magnetic Resonance Imaging of Fibroblast Activation Protein Using a Targeted Gadolinium-Based Contrast Agent. (PubMed, Mol Pharm)
Immunohistochemical analysis of harvested tumor tissue supported the above findings. Gd-DOTA-FAPI04 is a promising contrast agent for in vivo imaging of FAP.
Journal • MRI
|
FAP (Fibroblast activation protein, alpha)
3ms
Trypanosoma cruzi assembles host cytoplasmic processing bodies to evade the innate immune response. (PubMed, Biochim Biophys Acta Gen Subj)
Furthermore, the rescue of PB assembly in KO cells by GFP-tagged wild-type EDC4 (+WT) suppressed IL-1β expression, whereas KO cells with the C-terminal-deleted mutant EDC4 (+Δ) failed to rescue PB assembly and downregulate IL-1β production. Our results suggest that T. cruzi assembles host PBs to counteract antiparasitic innate immunity.
Journal
|
IL1B (Interleukin 1, beta)
4ms
Polyphyllin II Induces Apoptosis in Fibrosarcoma Cells via Activating Pyruvate Kinase M2. (PubMed, Chem Res Toxicol)
Moreover, PP2 reduced the proliferation and migration of HT-1080 cells. Thus, targeting the glycolysis pathway offers an unprecedented mode of action for comprehending PP2's pharmacological impacts and advances PP2's further development in fibrosarcoma therapy.
Journal
|
LDHA (Lactate dehydrogenase A) • NQO1 (NAD(P)H dehydrogenase, quinone 1) • PKM (Pyruvate Kinase M1/2) • SLC2A1 (Solute Carrier Family 2 Member 1)
4ms
Comparison of MMP-2, MMP-9, COX-2, and PGP Expression in Feline Injection-Site and Feline Noninjection-Site Sarcomas-Pilot Study. (PubMed, Animals (Basel))
A strong negative correlation between COX-2 and PGP (r = -0.81), a moderate positive correlation between MMP-2 and MMP-9 (r = +0.69), and a moderate negative correlation between MMP-2 and PGP (r = -0.44) were observed in non-FISS. In summary, our study presents the immunohistochemical profile of the proteins involved with inflammation and carcinogenesis in FISS and non-FISS, which can contribute to expanding the knowledge of tumor biology.
Journal
|
MMP2 (Matrix metallopeptidase 2) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • MMP9 (Matrix metallopeptidase 9)
4ms
Ticlopidine protects hepatic ischemia-reperfusion injury via suppressing ferroptosis. (PubMed, Biochem Biophys Res Commun)
The protective effects involved partial rescue of lipid peroxidation, significant reduction of ferrous iron levels, and strong protection against mitochondrial damage. These findings suggested that Ticlopidine acts as a broad-spectrum ferroptosis inhibitor, offering a promising therapeutic approach for protecting the liver against IRI.
Journal
|
PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
4ms
Benzimidazole-oxindole hybrids: A novel class of selective dual CDK2 and GSK-3β inhibitors of potent anticancer activity. (PubMed, Arch Pharm (Weinheim))
In silico docking of the benzimidazole-oxindole hybrid 8v into the catalytic pocket of both CDK2 and GSK-3β revealed its perfect fitting through the formation of hydrogen bonding and hydrophobic interactions with the key amino acids in the binding sites. In addition, in silico absorption, distribution, metabolism, excretion studies proved that 8a-x exhibit satisfactory drug-likeness properties for drug development.
Journal
|
KDR (Kinase insert domain receptor) • CDK1 (Cyclin-dependent kinase 1)
4ms
EWSR1::ATF1 fusions characterize a group of extra-abdominal epithelioid and round cell mesenchymal neoplasms, phenotypically overlapping with sclerosing epithelioid fibrosarcomas, and intra-abdominal FET::CREB fusion neoplasms. (PubMed, Virchows Arch)
Our cases point to a potentially aggressive clinical behavior. Recognizing this tumor type is mandatory to delineate any inherent biological and/or therapeutic distinctness from other, better-known sarcomas in the differential diagnosis including sclerosing epithelioid fibrosarcoma.
Journal
|
ALK (Anaplastic lymphoma kinase) • EWSR1 (EWS RNA Binding Protein 1) • SOX10 (SRY-Box 10) • FUS (FUS RNA Binding Protein) • MUC4 (Mucin 4, Cell Surface Associated) • ATF1 (Activating Transcription Factor 1) • SYP (Synaptophysin)
4ms
Unlocking immunotherapy targets: programmed death 1 and its ligand and their correlation with tumour grade in feline injection site sarcoma. (PubMed, J Comp Pathol)
A moderate correlation was also detected between PD-1 and PD-L1 (P <0.05). It was concluded that the increased expression of PD-1 and PD-L1 may be associated with poor tumour differentiation and, therefore, poor prognosis in FISS.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • VIM (Vimentin)
4ms
CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity. (PubMed, Front Immunol)
In this study, we investigated the intricate role of CX3CL1 in immunogenic apoptosis induced by mitoxantrone (MTX) in cancer cells...Furthermore, analysis of melanoma patient data revealed enhanced survival rates in individuals exhibiting elevated levels of CD8+ T cells expressing CX3CR1. These data collectively underscore the importance of the release of CX3CL1 in eliciting an immunogenic response against dying cancer cells and suggest that CX3CL1 may serve as a key switch in conferring immunogenicity to apoptosis.
Journal
|
CD8 (cluster of differentiation 8) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
|
mitoxantrone
4ms
Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice. (PubMed, Eur J Nucl Med Mol Imaging)
[225Ac]Ac-FAPI-46 efficacy is correlated with tumoral FAP expression levels and can restore responsiveness to PD-1 ICB. These data illustrate that careful patient selection based on target expression and rationally designed combination therapies are critically important to maximize the therapeutic impact of FAP-targeting radioligands.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
FAP (Fibroblast activation protein, alpha)
4ms
ALDH1+ tumor stem cells promote the progression of malignant fibrous tissue sarcoma by inhibiting SYNPO2 through hsa-mir-206. (PubMed, Exp Cell Res)
The results of CCK8 assay, scratch assay, and transwell assay showed that the proliferation and migration ability of NFMH-1 cells were promoted after SYNPO2 was inhibited. ALDH1+ tumor stem cells promote the proliferation and invasion of malignant fibrous histiocytoma cells by inhibiting SYNPO2 through hsa-mir-206.
Journal
|
CD8 (cluster of differentiation 8) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • MIR206 (MicroRNA 206)
4ms
A possible role of lncRNA MEG3 and lncRNA MAFG-AS1 on miRNA 147-b in the pathogenesis of Behcet's disease. (PubMed, Immunogenetics)
So, LncRNA MEG3, lncRNA MAFG-AS1, and miRNA147-b are promising diagnostic markers and therapeutic targets for BD patients. LncRNA MEG3 can be used as a predictor for new BD ocular involvement.
Journal • IO biomarker
|
MEG3 (Maternally Expressed 3) • MILIP (MYC Inducible LncRNA Inactivating P53)
4ms
Release of Exosomal PD-L1 in Bone and Soft Tissue Sarcomas and Its Relationship to Radiotherapy. (PubMed, Cancers (Basel))
(4) Exosomal PD-L1 emanates from bone and soft tissue sarcoma cells and is disseminated into the circulatory system. The levels of PD-L1 in tumor cells and the release of exosomal PD-L1 were augmented after irradiation with RT.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
4ms
YAP1∷KMT2A fusion-positive sarcoma: An emerging soft tissue tumor entity with morphological features resembling a sclerosing epithelioid fibrosarcoma. (PubMed, Indian J Pathol Microbiol)
Thus, YAP1∷KMT2A positive sarcomas have distinct molecular and overlapping histopathological features with SEF, with relatively less aggressive disease course. Documentation of additional similar tumors with long-term follow-up is required.
Journal
|
CCND1 (Cyclin D1) • KMT2A (Lysine Methyltransferase 2A) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • EWSR1 (EWS RNA Binding Protein 1) • YAP1 (Yes associated protein 1) • MUC4 (Mucin 4, Cell Surface Associated) • STAT6 (Signal transducer and activator of transcription 6) • MYOD1 (Myogenic Differentiation 1) • S100P (S100 calcium binding protein P)
5ms
Journal
|
MSI (Microsatellite instability) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ETV6 (ETS Variant Transcription Factor 6) • RAD51B (RAD51 Paralog B) • TPM3 (Tropomyosin 3) • NTRK (Neurotrophic receptor tyrosine kinase) • DAB2IP (DAB2 Interacting Protein)
5ms
Expression of programmed cell death protein 1 and programmed cell death ligand 1 in feline injection site fibrosarcomas. (PubMed, Res Vet Sci)
Moreover, this study contributes to a deeper understanding of feline injection site fibrosarcoma pathogenesis, emphasizing the importance of considering immunological perspectives in developing effective treatment strategies for this challenging condition. Further investigations are warranted to advance our knowledge and refine therapeutic approaches for feline injection site fibrosarcoma management.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
5ms
Tumor microenvironment reprogramming improves nanomedicine-based chemo-immunotherapy in sarcomas. (PubMed, Mol Cancer Ther)
Collectively, our findings provide evidence that ketotifen-induced TME reprograming can improve the efficacy of nanomedicine-based chemoimmunotherapy in sarcomas.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
pegylated liposomal doxorubicin